RE: HEMO,s mouse model24 May 2018 03:25
“This agreement with Rockefeller has the potential to extend our product candidate opportunities into a new and exciting area, and we would fully expect to see the work funded through future non-dilutive grant funding. Shareholders can now also see the potential for the use of our technology beyond our current bone marrow transplantation focus to treat debilitating and otherwise incurable autoimmune diseases such as Lupus,” Vladislav Sandler, PhD, CEO and co-founder of Hemogenyx, said in a press release.